#	Pagina
attuale pagina	/open-h2020/projects/199228/index.html
-1	/open-h2020/per-topic/synaptogenesis/list/index.html
-2	/open-h2020/projects/196489/index.html
-3	/open-h2020/per-topic/qualifies/list/index.html

Opendata, web and dolomites

BACRES

Feasibility study: Cloud-based diagnostic software for infectious diseases

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

BACRES project word cloud

Explore the words cloud of the BACRES project. It provides you a very rough idea of what is the project "BACRES" about.

care resource advantage thing profiles sampling diagnosis 2017 intensive annually clinical diagnostic antibiotic dna 55 resistant identification give world resistance combines ing ce infections market takes complete patient confer download demands threats organization generation minutes deaths upload tests ngs 15 software bioinformatics society ineffective worth human recourse validation shortened version proprietary hospital modern direct cloud million billion transmission laboratory automatically 48 bacteria connection platform computing excess efficient solution doctor sequencing 12 diminished routine data internet marking consuming contributor slow raw time bacterial first treatment gt longer launch health bn customers service decision mortality hours healthcare 1928 feasibility diagnostics

Project "BACRES" data sheet

The following table provides information about the project.

Coordinator	1928DIAGNOSTICS AB Organization address address: STENA CENTER 1D city: GOTEBORG postcode: 412 92 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	http://www.1928diagnostics.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-12-01 to 2016-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	1928DIAGNOSTICS AB 1928DIAGNOSTICS AB Organization address address: STENA CENTER 1D city: GOTEBORG postcode: 412 92 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (GOTEBORG)	coordinator	50˙000.00

Map

Project objective

The problem of antibiotic resistance is considered one of the largest threats to human health by the World Health Organization (WHO). In EU and the US antibiotic resistance infections have been estimated to cause > 48 000 deaths from 2,5 million resistant infections and confer an excess direct healthcare cost of € 20 billion annually. A major contributor to this is current diagnostic methods, being slow (longer than 48 hours), resource-consuming and/or non comprehensive resulting in ineffective treatment. 1928 Diagnostics is developing a software solution that takes advantage of modern DNA technology (next generation sequencing, NGS) that is currently not used in clinical routine due to complex data analysis that is time and recourse intensive. Our solution is a software-as-a-service that combines cloud computing and a proprietary bioinformatics platform that automatically processes large and complex data to give resistance profiles as well as bacterial identification in just 15 minutes, enabling complete diagnosis in under 12 hours. The only thing required at the hospital laboratory is an internet connection in order to upload NGS raw data and to download the resistance profiles that will be used as a decision support for the doctor in the treatment selection for a particular patient. The result is shortened time from patient sampling to treatment, resulting in reduced mortality, less transmission of resistant bacteria and diminished costs for the health care system and society. Our product addresses a market that is worth over € 8 BN based on 55 million potential tests in EU and US. The feasibility study will focus on understanding the customers and market demands for the first version of the product in order to reach the market in the most efficient way. In a following Phase 2 project activities will include product development, clinical validation studies and CE marking activities to support product launch in 2017.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BACRES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BACRES" are provided by the European Opendata Portal: CORDIS opendata.